CymitQuimica logo

6-Amino-5-bromo-1-methyluracil monohydrate

Ref. 3D-FA17609

100mg
Discontinued
250mg
Discontinued

Discontinued product. For inquiries about similar products, please fill out our form or email us at .

6-Amino-5-bromo-1-methyluracil monohydrate
Biosynth

    Product Information

    Name:6-Amino-5-bromo-1-methyluracil monohydrate
    Synonyms:
    • 6-Amino-5-bromo-1-methyl-2,4(1H,3H)-pyrimidinedione1-Methyl-5-bromo-6-aminouracil6-Amino-5-bromo-1-methyl-1H-pyrimidine-2,4-dione
    Brand:Biosynth
    Description:6-Amino-5-bromo-1-methyluracil monohydrate (6ABMU) is a purine analogue that has been shown to be a potent and selective inhibitor of the enzyme uracil phosphoribosyltransferase, which is involved in the synthesis of uridine monophosphate. 6ABMU has been used for research purposes and can be administered orally or intravenously. This drug also has been shown to increase the production of propylamine, an intermediate in the metabolism of methylated purines. The pharmacokinetics of 6ABMU have been studied in rats, mice, and humans and has been found to have a half-life of about one hour. Metrics such as the bioavailability and plasma protein binding have also been determined for this drug. Biostructural studies on 6ABMU have shown that it binds to proteins with high affinity and specificity; these proteins include protein-protein interactions such as those between rib
    Notice:Our products are intended for lab use only. For any other use, please contact us.

    Chemical properties

    Molecular weight:238.04 g/mol
    Formula:C5H6BrN3O2·H2O
    Purity:Min. 95%
    Color/Form:White to pale yellow solid.

    Inquiry about discontinued product: 6-Amino-5-bromo-1-methyluracil monohydrate

    ◻️
    CYMIT QUÍMICA, S.L. as responsible for the treatment will treat your data in order to respond to your queries or requests. You can access, rectify and delete your data, as well as exercise other rights by consulting the additional and detailed information on data protection in our Web Privacy Policy.
    * Mandatory fields.